Read + Share
Upadhyaya SA, Campagne O, Billups CA, Orr BA, et al. Phase II study of alisertib as a single agent for treating recurrent or
progressive atypical teratoid/rhabdoid tumor. Neuro Oncol 2023;25:386-397.
PMID: 35652336
|
 |
|
Upadhyaya SA, Campagne O, Billups CA, Orr BA, et al. Phase II study of alisertib as a single agent for treating recurrent or
progressive atypical teratoid/rhabdoid tumor. Neuro Oncol 2023;25:386-397.
PMID: 35652336
|
|
|
|